JP7060216B2 - 多様な選択された臓器又は組織をターゲティングするための物質 - Google Patents
多様な選択された臓器又は組織をターゲティングするための物質 Download PDFInfo
- Publication number
- JP7060216B2 JP7060216B2 JP2019526295A JP2019526295A JP7060216B2 JP 7060216 B2 JP7060216 B2 JP 7060216B2 JP 2019526295 A JP2019526295 A JP 2019526295A JP 2019526295 A JP2019526295 A JP 2019526295A JP 7060216 B2 JP7060216 B2 JP 7060216B2
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- moiety
- biologically active
- conjugate
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000008685 targeting Effects 0.000 title claims description 66
- 239000000126 substance Substances 0.000 title description 22
- 210000000056 organ Anatomy 0.000 title description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 253
- 150000001413 amino acids Chemical class 0.000 claims description 58
- 108090000623 proteins and genes Proteins 0.000 claims description 44
- 102000004169 proteins and genes Human genes 0.000 claims description 32
- 238000011282 treatment Methods 0.000 claims description 25
- 125000003729 nucleotide group Chemical group 0.000 claims description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 23
- 210000000663 muscle cell Anatomy 0.000 claims description 23
- 108091034117 Oligonucleotide Proteins 0.000 claims description 20
- 125000005647 linker group Chemical group 0.000 claims description 20
- 239000002773 nucleotide Substances 0.000 claims description 18
- 201000006938 muscular dystrophy Diseases 0.000 claims description 16
- 108020004707 nucleic acids Proteins 0.000 claims description 16
- 102000039446 nucleic acids Human genes 0.000 claims description 16
- 125000000539 amino acid group Chemical group 0.000 claims description 15
- 125000004122 cyclic group Chemical group 0.000 claims description 15
- 208000021642 Muscular disease Diseases 0.000 claims description 14
- 201000009623 Myopathy Diseases 0.000 claims description 12
- 208000035475 disorder Diseases 0.000 claims description 11
- 201000000585 muscular atrophy Diseases 0.000 claims description 8
- 206010028289 Muscle atrophy Diseases 0.000 claims description 7
- 239000003550 marker Substances 0.000 claims description 7
- 208000023275 Autoimmune disease Diseases 0.000 claims description 6
- 108010077850 Nuclear Localization Signals Proteins 0.000 claims description 6
- 208000008589 Obesity Diseases 0.000 claims description 6
- 108091093037 Peptide nucleic acid Proteins 0.000 claims description 6
- 208000019622 heart disease Diseases 0.000 claims description 6
- 208000030159 metabolic disease Diseases 0.000 claims description 6
- 235000020824 obesity Nutrition 0.000 claims description 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 6
- 208000020446 Cardiac disease Diseases 0.000 claims description 5
- 238000001514 detection method Methods 0.000 claims description 5
- 108020001507 fusion proteins Proteins 0.000 claims description 5
- 102000037865 fusion proteins Human genes 0.000 claims description 5
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 229940024606 amino acid Drugs 0.000 description 60
- 235000001014 amino acid Nutrition 0.000 description 59
- 239000000074 antisense oligonucleotide Substances 0.000 description 58
- 238000012230 antisense oligonucleotides Methods 0.000 description 58
- 102000004196 processed proteins & peptides Human genes 0.000 description 58
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 57
- 210000004027 cell Anatomy 0.000 description 42
- 108010069514 Cyclic Peptides Proteins 0.000 description 37
- 102000001189 Cyclic Peptides Human genes 0.000 description 37
- 150000001875 compounds Chemical class 0.000 description 34
- 239000000178 monomer Substances 0.000 description 34
- 239000003814 drug Substances 0.000 description 32
- 235000018102 proteins Nutrition 0.000 description 30
- 241000699670 Mus sp. Species 0.000 description 26
- 229940079593 drug Drugs 0.000 description 26
- 210000001519 tissue Anatomy 0.000 description 25
- 210000003205 muscle Anatomy 0.000 description 24
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 20
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 19
- 238000011156 evaluation Methods 0.000 description 19
- 108020004414 DNA Proteins 0.000 description 18
- -1 antibodies Substances 0.000 description 18
- 238000002347 injection Methods 0.000 description 18
- 239000007924 injection Substances 0.000 description 18
- 238000000034 method Methods 0.000 description 18
- 210000002027 skeletal muscle Anatomy 0.000 description 18
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 17
- 238000001727 in vivo Methods 0.000 description 17
- 210000004413 cardiac myocyte Anatomy 0.000 description 15
- 230000001225 therapeutic effect Effects 0.000 description 15
- 238000000338 in vitro Methods 0.000 description 14
- 102000003929 Transaminases Human genes 0.000 description 13
- 108090000340 Transaminases Proteins 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 108010069091 Dystrophin Proteins 0.000 description 12
- 102100024108 Dystrophin Human genes 0.000 description 12
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical group CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 12
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 210000002216 heart Anatomy 0.000 description 11
- 150000007523 nucleic acids Chemical class 0.000 description 11
- 210000004185 liver Anatomy 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 108020004999 messenger RNA Proteins 0.000 description 10
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 10
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 9
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 9
- 230000021615 conjugation Effects 0.000 description 9
- 210000003734 kidney Anatomy 0.000 description 9
- 239000012120 mounting media Substances 0.000 description 9
- 238000002823 phage display Methods 0.000 description 9
- 201000006935 Becker muscular dystrophy Diseases 0.000 description 8
- 102000004420 Creatine Kinase Human genes 0.000 description 8
- 108010042126 Creatine kinase Proteins 0.000 description 8
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 8
- 241000700605 Viruses Species 0.000 description 8
- 125000000217 alkyl group Chemical group 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 230000027455 binding Effects 0.000 description 8
- 238000009739 binding Methods 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 239000004202 carbamide Substances 0.000 description 8
- 230000008878 coupling Effects 0.000 description 8
- 238000010168 coupling process Methods 0.000 description 8
- 238000005859 coupling reaction Methods 0.000 description 8
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 7
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 7
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 7
- 102000001554 Hemoglobins Human genes 0.000 description 7
- 108010054147 Hemoglobins Proteins 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 7
- 235000018417 cysteine Nutrition 0.000 description 7
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 229930195712 glutamate Natural products 0.000 description 7
- WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 7
- 238000012384 transportation and delivery Methods 0.000 description 7
- HWKRAUXFMLQKLS-UHFFFAOYSA-N 2-oxidanylidenepropanoic acid Chemical group CC(=O)C(O)=O.CC(=O)C(O)=O HWKRAUXFMLQKLS-UHFFFAOYSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 6
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 108091000080 Phosphotransferase Proteins 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 125000003275 alpha amino acid group Chemical group 0.000 description 6
- 230000000692 anti-sense effect Effects 0.000 description 6
- 229940109239 creatinine Drugs 0.000 description 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 210000004165 myocardium Anatomy 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 150000004713 phosphodiesters Chemical group 0.000 description 6
- 102000020233 phosphotransferase Human genes 0.000 description 6
- 210000003314 quadriceps muscle Anatomy 0.000 description 6
- TWGNOYAGHYUFFR-UHFFFAOYSA-N 5-methylpyrimidine Chemical compound CC1=CN=CN=C1 TWGNOYAGHYUFFR-UHFFFAOYSA-N 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 108700024394 Exon Proteins 0.000 description 5
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 5
- 239000004472 Lysine Substances 0.000 description 5
- 108020004459 Small interfering RNA Proteins 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000002032 lab-on-a-chip Methods 0.000 description 5
- 238000000386 microscopy Methods 0.000 description 5
- 238000007481 next generation sequencing Methods 0.000 description 5
- 238000001543 one-way ANOVA Methods 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 238000003757 reverse transcription PCR Methods 0.000 description 5
- 238000007363 ring formation reaction Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000014616 translation Effects 0.000 description 5
- 230000003442 weekly effect Effects 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 4
- 101001018026 Homo sapiens Lysosomal alpha-glucosidase Proteins 0.000 description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
- 102100022745 Laminin subunit alpha-2 Human genes 0.000 description 4
- 101001053945 Mus musculus Dystrophin Proteins 0.000 description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 4
- 108010067902 Peptide Library Proteins 0.000 description 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N THREONINE Chemical compound CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 4
- 150000001345 alkine derivatives Chemical class 0.000 description 4
- 229960002684 aminocaproic acid Drugs 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 201000006815 congenital muscular dystrophy Diseases 0.000 description 4
- 229940104302 cytosine Drugs 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 4
- 102000045921 human GAA Human genes 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 4
- 230000002107 myocardial effect Effects 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 244000045947 parasite Species 0.000 description 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 239000004055 small Interfering RNA Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 229940035893 uracil Drugs 0.000 description 4
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 description 3
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- 206010053185 Glycogen storage disease type II Diseases 0.000 description 3
- 208000023105 Huntington disease Diseases 0.000 description 3
- 208000026350 Inborn Genetic disease Diseases 0.000 description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 150000001408 amides Chemical group 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 125000002091 cationic group Chemical group 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 208000016361 genetic disease Diseases 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 201000004502 glycogen storage disease II Diseases 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
- 229960000310 isoleucine Drugs 0.000 description 3
- 230000003387 muscular Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 210000003098 myoblast Anatomy 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N serine Chemical compound OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- 210000002363 skeletal muscle cell Anatomy 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 229940124530 sulfonamide Drugs 0.000 description 3
- 150000003456 sulfonamides Chemical class 0.000 description 3
- 238000012385 systemic delivery Methods 0.000 description 3
- 150000003573 thiols Chemical class 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 102000014461 Ataxins Human genes 0.000 description 2
- 108010078286 Ataxins Proteins 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- 206010008025 Cerebellar ataxia Diseases 0.000 description 2
- 150000008574 D-amino acids Chemical class 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 208000024412 Friedreich ataxia Diseases 0.000 description 2
- 201000011240 Frontotemporal dementia Diseases 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 150000008575 L-amino acids Chemical class 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 102100033448 Lysosomal alpha-glucosidase Human genes 0.000 description 2
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000029578 Muscle disease Diseases 0.000 description 2
- 102000004472 Myostatin Human genes 0.000 description 2
- 108010056852 Myostatin Proteins 0.000 description 2
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 2
- 108091027967 Small hairpin RNA Proteins 0.000 description 2
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 108700005077 Viral Genes Proteins 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 description 2
- 150000001540 azides Chemical class 0.000 description 2
- 229940000635 beta-alanine Drugs 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 229960004203 carnitine Drugs 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 125000000000 cycloalkoxy group Chemical group 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 150000002019 disulfides Chemical class 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002641 enzyme replacement therapy Methods 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 150000004702 methyl esters Chemical group 0.000 description 2
- 108091070501 miRNA Proteins 0.000 description 2
- 239000002679 microRNA Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000002161 motor neuron Anatomy 0.000 description 2
- 208000018360 neuromuscular disease Diseases 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000000816 peptidomimetic Substances 0.000 description 2
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 150000003852 triazoles Chemical class 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- JKHVDAUOODACDU-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(2,5-dioxopyrrol-1-yl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCN1C(=O)C=CC1=O JKHVDAUOODACDU-UHFFFAOYSA-N 0.000 description 1
- VJLXSTXGGXYQCT-BKLSDQPFSA-N (2s)-3-aminopyrrolidine-2-carboxylic acid Chemical compound NC1CCN[C@@H]1C(O)=O VJLXSTXGGXYQCT-BKLSDQPFSA-N 0.000 description 1
- 125000004642 (C1-C12) alkoxy group Chemical group 0.000 description 1
- 125000006710 (C2-C12) alkenyl group Chemical group 0.000 description 1
- 125000006711 (C2-C12) alkynyl group Chemical group 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- JHTPBGFVWWSHDL-UHFFFAOYSA-N 1,4-dichloro-2-isothiocyanatobenzene Chemical compound ClC1=CC=C(Cl)C(N=C=S)=C1 JHTPBGFVWWSHDL-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- ABEXEQSGABRUHS-UHFFFAOYSA-N 16-methylheptadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C ABEXEQSGABRUHS-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- RCZUDMZUWULMID-UHFFFAOYSA-N 2-nitrotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(O)C=C1[N+]([O-])=O RCZUDMZUWULMID-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- QCHPKSFMDHPSNR-UHFFFAOYSA-N 3-aminoisobutyric acid Chemical compound NCC(C)C(O)=O QCHPKSFMDHPSNR-UHFFFAOYSA-N 0.000 description 1
- AUDYZXNUHIIGRB-UHFFFAOYSA-N 3-thiophen-2-ylpyrrole-2,5-dione Chemical compound O=C1NC(=O)C(C=2SC=CC=2)=C1 AUDYZXNUHIIGRB-UHFFFAOYSA-N 0.000 description 1
- XWHHYOYVRVGJJY-QMMMGPOBSA-N 4-fluoro-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(F)C=C1 XWHHYOYVRVGJJY-QMMMGPOBSA-N 0.000 description 1
- ASYBZHICIMVQII-UHFFFAOYSA-N 4-hydroxylysine Chemical compound NCCC(O)CC(N)C(O)=O ASYBZHICIMVQII-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 1
- ZZOKVYOCRSMTSS-UHFFFAOYSA-N 9h-fluoren-9-ylmethyl carbamate Chemical group C1=CC=C2C(COC(=O)N)C3=CC=CC=C3C2=C1 ZZOKVYOCRSMTSS-UHFFFAOYSA-N 0.000 description 1
- 239000013607 AAV vector Substances 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 108010029692 Bisphosphoglycerate mutase Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 208000015374 Central core disease Diseases 0.000 description 1
- 201000003728 Centronuclear myopathy Diseases 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 102100023804 Coagulation factor VII Human genes 0.000 description 1
- 108020004394 Complementary RNA Proteins 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 108010002156 Depsipeptides Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 108010023321 Factor VII Proteins 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000016354 Glucuronosyltransferase Human genes 0.000 description 1
- 108010092364 Glucuronosyltransferase Proteins 0.000 description 1
- 208000032007 Glycogen storage disease due to acid maltase deficiency Diseases 0.000 description 1
- 208000032008 Glycogen storage disease due to glycogen debranching enzyme deficiency Diseases 0.000 description 1
- 206010053250 Glycogen storage disease type III Diseases 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 101000945318 Homo sapiens Calponin-1 Proteins 0.000 description 1
- 101001053946 Homo sapiens Dystrophin Proteins 0.000 description 1
- 101000652736 Homo sapiens Transgelin Proteins 0.000 description 1
- 101150043003 Htt gene Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 208000029400 Inclusion myopathy Diseases 0.000 description 1
- 241000764238 Isis Species 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- AGPKZVBTJJNPAG-UHNVWZDZSA-N L-allo-Isoleucine Chemical compound CC[C@@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-UHNVWZDZSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical group OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- JTTHKOPSMAVJFE-VIFPVBQESA-N L-homophenylalanine Chemical compound OC(=O)[C@@H](N)CCC1=CC=CC=C1 JTTHKOPSMAVJFE-VIFPVBQESA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- 208000015439 Lysosomal storage disease Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 201000002169 Mitochondrial myopathy Diseases 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- 208000010316 Myotonia congenita Diseases 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010043958 Peptoids Proteins 0.000 description 1
- 102000001105 Phosphofructokinases Human genes 0.000 description 1
- 108010069341 Phosphofructokinases Proteins 0.000 description 1
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 description 1
- 102000011025 Phosphoglycerate Mutase Human genes 0.000 description 1
- 102000009097 Phosphorylases Human genes 0.000 description 1
- 108010073135 Phosphorylases Proteins 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical class C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 1
- ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 101150015954 SMN2 gene Proteins 0.000 description 1
- 241001635911 Sarepta Species 0.000 description 1
- 241001522306 Serinus serinus Species 0.000 description 1
- 244000191761 Sida cordifolia Species 0.000 description 1
- 102000039471 Small Nuclear RNA Human genes 0.000 description 1
- 208000032978 Structural Congenital Myopathies Diseases 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- DPOPAJRDYZGTIR-UHFFFAOYSA-N Tetrazine Chemical compound C1=CN=NN=N1 DPOPAJRDYZGTIR-UHFFFAOYSA-N 0.000 description 1
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 1
- 208000010641 Tooth disease Diseases 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 102100031013 Transgelin Human genes 0.000 description 1
- 241000710779 Trina Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 150000003869 acetamides Chemical group 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229940022705 aldurazyme Drugs 0.000 description 1
- 125000003302 alkenyloxy group Chemical group 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 125000005133 alkynyloxy group Chemical group 0.000 description 1
- WNNNWFKQCKFSDK-UHFFFAOYSA-N allylglycine Chemical compound OC(=O)C(N)CC=C WNNNWFKQCKFSDK-UHFFFAOYSA-N 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 229940059260 amidate Drugs 0.000 description 1
- 125000002344 aminooxy group Chemical group [H]N([H])O[*] 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 208000031375 autosomal dominant myotonia congenita Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- PUJDIJCNWFYVJX-UHFFFAOYSA-N benzyl carbamate Chemical group NC(=O)OCC1=CC=CC=C1 PUJDIJCNWFYVJX-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000015861 cell surface binding Effects 0.000 description 1
- 201000007303 central core myopathy Diseases 0.000 description 1
- 229940049197 cerezyme Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013501 data transformation Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- KZNICNPSHKQLFF-UHFFFAOYSA-N dihydromaleimide Natural products O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 201000009338 distal myopathy Diseases 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 201000010048 endomyocardial fibrosis Diseases 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- NPUKDXXFDDZOKR-LLVKDONJSA-N etomidate Chemical group CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1 NPUKDXXFDDZOKR-LLVKDONJSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 229960004222 factor ix Drugs 0.000 description 1
- 229940012413 factor vii Drugs 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 230000008303 genetic mechanism Effects 0.000 description 1
- 201000004543 glycogen storage disease III Diseases 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 238000005417 image-selected in vivo spectroscopy Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 150000003949 imides Chemical class 0.000 description 1
- 108010039650 imiglucerase Proteins 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000012750 in vivo screening Methods 0.000 description 1
- 208000023692 inborn mitochondrial myopathy Diseases 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000012739 integrated shape imaging system Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 150000002678 macrocyclic compounds Chemical class 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000005649 metathesis reaction Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 229940103023 myozyme Drugs 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- JFNLZVQOOSMTJK-KNVOCYPGSA-N norbornene Chemical compound C1[C@@H]2CC[C@H]1C=C2 JFNLZVQOOSMTJK-KNVOCYPGSA-N 0.000 description 1
- 230000025308 nuclear transport Effects 0.000 description 1
- 230000031787 nutrient reservoir activity Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical class C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 238000005897 peptide coupling reaction Methods 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 208000000943 scapulohumeral muscular dystrophy Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 108091029842 small nuclear ribonucleic acid Proteins 0.000 description 1
- 210000001057 smooth muscle myoblast Anatomy 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 208000002320 spinal muscular atrophy Diseases 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- XBXCNNQPRYLIDE-UHFFFAOYSA-N tert-butylcarbamic acid Chemical group CC(C)(C)NC(O)=O XBXCNNQPRYLIDE-UHFFFAOYSA-N 0.000 description 1
- 150000004905 tetrazines Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 125000003441 thioacyl group Chemical group 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229920000428 triblock copolymer Polymers 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
- A61K49/0043—Fluorescein, used in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0056—Peptides, proteins, polyamino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
- C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/13—Labelling of peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
Description
本発明に従うペプチド又はペプチド模倣体と、
前記ペプチド又はペプチド模倣体を、生物学的活性部分又は診断用部分へと連結するためのリンカー部分であって、ペプチドではないリンカー部分と
を含む分子も提供する。
本明細書では、このような分子を、本発明に従う分子と称する。
i)2’-F単量体、2’-O-メチル単量体、2’-アミノ単量体、又は2’-O-(2-メトキシエチル)単量体、最も好ましくは、2’-O-メチル単量体であることが好ましい、2’-置換単量体;
ii)シトシン塩基を置換する、少なくとも1つの5-メチルシトシン塩基;
iii)全てのシトシン塩基を置換する、5-メチルシトシン塩基;
iv)ウラシル塩基を置換する、少なくとも1つの5-メチルウラシル塩基;
v)全てのウラシル塩基を置換する、5-メチルウラシル塩基;
vi)ホスホジエステル骨格連結を置換する、少なくとも1つのホスホロチオエート骨格連結;
vii)全てのホスホジエステル骨格連結を置換する、ホスホロチオエート骨格連結;
viii)上記で記載した類似体の単量体など、少なくとも1つの類似体の単量体
のうちの1又は複数を含む。
i)好ましくは、2’-F単量体、2’-O-メチル単量体、2’-アミノ単量体、又は2’-O-(2-メトキシエチル)単量体、最も好ましくは、2’-O-メチル単量体である、2’-置換単量体;
ii)シトシン塩基を置換する、少なくとも1つの5-メチルシトシン塩基;
iii)全てのシトシン塩基を置換する、5-メチルシトシン塩基;
iv)ウラシル塩基を置換する、少なくとも1つの5-メチルウラシル塩基;
v)全てのウラシル塩基を置換する、5-メチルウラシル塩基;
vi)ホスホジエステル骨格連結を置換する、少なくとも1つのホスホロチオエート骨格連結;
vii)全てのホスホジエステル骨格連結を置換する、ホスホロチオエート骨格連結;
viii)本明細書の前出で記載した類似体の単量体など、少なくとも1つの類似体の単量体
のうちの1又は複数を含むAONである、本発明に従うコンジュゲートも提供する。
LTLPWSK VKHKSLD FSHTYRV QLFPLFR TLQDQAT LLGHTNN IAWNKQG SLFKNSR RENTNHT QVRSNTT KTGHAHL TYSPTEV KYMSSHA LNSLFGS KDPRPAL RADFYTT WNEDHTW MQHSMRV LPDAYHV SRFQLPQ LKSAGNN VSPSKSF YGTGNNY DPRTQPH YETSKES
からなる群から選択される、本発明に従うペプチド又はペプチド模倣体が提供される。
好ましくは、ターゲティング配列は、
FSHTYRV QLFPLFR TLQDQAT SLFKNSR RENTNHT QVRSNTT TYSPTEV LNSLFGS RADFYTT WNEDHTW MQHSMRV LLGHTNN
からなる群から選択される。
より好ましくは、ターゲティング配列は、
LNSLFGS QLFPLFR
からなる群から選択される。
本発明は、オリゴヌクレオチド、遺伝子、タンパク質、医薬などの生物学的活性部分を、多様な臓器又は組織、とりわけ、筋細胞及び心臓へとターゲティングするための、ペプチド又はペプチド模倣体を提供する。したがって、本発明はまた、好ましくは、生物学的活性部分又は診断用部分を、筋細胞へとターゲティングするための、本発明に従うペプチド、又は本発明に従うコンジュゲートの、医薬としての使用にも関する。したがって、第2の態様では、本発明は、医薬としての使用のための、本発明に従うペプチドを提供する。こうして、本発明は、医薬としての使用のための、配列番号1~63(好ましくは、配列番号24又は25)からなる群から選択される、ターゲティング配列を含むか、又はこれらからなる、ペプチド又はペプチド模倣体を提供する。好ましくは、本発明に従う、このようなペプチドは、本発明に従うコンジュゲートに含まれる。したがって、第2の態様では、本発明は、医薬としての使用のための、本発明に従うコンジュゲートを提供する。本明細書では、使用のためのこれらのペプチドを、本発明に従う使用のためのペプチドと称する。本明細書では、使用のためのこれらのコンジュゲートを、本発明に従う使用のためのコンジュゲートと称する。この態様についての、好ましい実施形態では、本発明は、生物学的活性部分又は診断用部分を、筋細胞へとターゲティングするための、本発明に従う使用のためのペプチドを提供する。この態様についての、好ましい実施形態では、本発明は、生物学的活性部分又は診断用部分を、筋細胞へとターゲティングするための、本発明に従う使用のためのコンジュゲートを提供する。
本出願では、「物質」とは、純粋な分子、複数の異なる分子の複合体、オリゴマー、ポリマー、ポリペプチド、タンパク質、粒子、又はこれらの断片として解釈されるべきである。
全ての細胞を、37℃及び5%CO2のインキュベーターにおいて培養した。ヒト対照筋芽細胞(ファージディスプレイバイオパニングのために使用される7304-1細胞(Zhuら、2007))を、細胞培養(Nutacon B.V.Netherlands)のための、精製ウシ皮膚コラーゲン(コラーゲン)でコーティングされたフラスコの、グルタマックスI(GlutaMax-I)、20%のウシ胎仔血清(FBS)、及び1%のペニシリン/ストレプトマイシン(P/S)(全てGibco-BRL、Netherlands製)を補充した、ナットミックスF-10(NutMix F-10)(Ham’s)培地において増殖させた。細胞を、コラーゲンでコーティングしたペトリディッシュに播種し、90%コンフルエンスまで増殖させてから、分化培地(2%のFBS、1%のP/S、2%のグルタマックス、及び1%のグルコース(全てGibco-BRL、Netherlands製)を伴う(フェノールレッドを伴わない)ダルベッコ培地)へと切り替えた。細胞を、7~14日間にわたり分化させた。
ファージディスプレイによる選択実験及び候補ペプチドの同定についての概観(図1)
in vitroにおけるバイオパニング
in vivoにおけるバイオパニング
全ファージDNAを、単一のラウンドの細菌増幅の後で、濃縮された全てのファージライブラリー、ナイーブ非選択ライブラリー、及びナイーブライブラリーから単離した。濃縮された各ファージライブラリーから、ファージ粒子2×1011個を、1.5mlのチューブの、500μlのLB増殖培地へと添加した。ファージを、200μlのPEG 8000/NaClにより、室温で、3~4時間にわたり沈殿させた。ファージをペレット化し、DNAを、製造元の指示書に従い単離した。最終的なペレット(ファージDNA)を、ミリキュー(milliQ)水に溶解させ、DNA濃度を、ナノドロップ(Nanodrop)(Thermo scientific)により決定した。ファージDNAを、以下のプライマー(*は、ホスホロチオエート結合である):
順方向:AAT GAT ACG GCG ACC ACC GAG ATC TAC ACT TCC TTT AGT GGT ACC TTT CTA TTC TC*A(配列番号64)
逆方向:CAA GCA GAA GAC GGC ATA CGA GAT CGG XXX XXX XXX ATG GGA TTT TGC TAA ACA ACT TT*C(配列番号65)
を使用するPCRにより増幅した。
イルミナカサバ1.8.2ソフトウェア(Illumina CASAVA 1.8.2 software)を使用して、Illumina BCLファイルから、fastqファイルを抽出し、個々の試料バーコードに基づき、データを分割した。さらなる解析のために、配列が、以下の基準を満たさない場合、配列にフィルターをかけた:配列は、GCT TGTで始まり、(NNK)7を後続させ、TGC GGT GGA GGTで終わり、Nは、任意のヌクレオチドであり、Kは、G又はTである。その後、従来のアミノ酸コドン表を使用する、カスタムのperlスクリプトにより、配列を、アミノ酸配列へと翻訳した。終止コドンであるTAGに遭遇したら、製造元の指示書(NEB)に従い、これを、CAGコドン(アミノ酸グルタミン)へと変化させた。カバレッジについての概観を、表2及び図1に示す。シーケンシングされた全てのファージライブラリーデータは、カウントデータにおける分散を安定化させるのに一般に適用されるデータ変換である、ライブラリーにおけるカウント数に対する平方根変換により正規化した(’t Hoenら、2008a)。その後、パラサイト配列を除外した。パラサイト配列は、増幅されたナイーブライブラリーにおける頻度カウントから、増幅されていないナイーブライブラリーにおける頻度カウントを減じた値が、2より大きい配列として規定した。次に、2つの別個の解析を実施した。第1に、肝臓及び/又は腎臓において、頻度カウントが2より大きな配列を、濃縮された骨格筋ライブラリー及び心筋ライブラリーから除外した。骨格筋ライブラリー及び心筋ライブラリーにおける配列を、ライブラリーごとに、頻度カウントによりランクづけし、重要な候補配列を、2つの群、すなわち、「骨格筋」及び「心筋」に分けた。第2に、肝臓ライブラリー及び腎臓ライブラリーについての閾値を無視し、骨格筋ライブラリー及び心筋ライブラリーを、頻度カウントに基づきランクづけした。肝臓及び/又は腎臓において、カウントが、骨格又は心筋と比較して高頻度のペプチド配列を除去した。
蛍光標識化されたペプチドは、イソチオシアン酸フルオレセイン(FITC)を使用して標識化し、Pepscan(Lelystad、Netherlands)から得た。FITC標識を、ペプチドのN末端へと付加された、Ahx(6-アミノヘキサン酸)スペーサーへと接合させ、C末端の一部をアミド化し、ペプチドを、ジスルフィド環化により、環状とした。本発明に従うペプチドは、システインによるフランキング部分を有し、フランキング部分は、ターゲティング配列である、配列番号14~25と直接隣接した。
Cys残基を、Ala残基で置き換えた、配列番号24又は配列番号25を含むペプチドの直鎖バージョンを、上記で記載した通りに標識化し、ヒト対照筋管と共に、3時間にわたりインキュベートした(図3D)。これらの変化形は、蛍光を示さない。
5’-カルボキシレートリンカーホスホルアミダイトは、Link Technologies(Bellshill、UK)から購入した。全ての溶媒及び試薬は、Sigma Aldrich(Zwijndrecht、Netherlands)又はAcros(Geel、Belgium)から得、そうでないことが指し示されない限りにおいて、受領した状態で使用した。観察された分子量は、参照標準値に照らして補正した。環状ペプチドは、PepScan(Lelystad、Netherlands)又はBachem(Bubendorf、Switzerland)により合成し、C末端にアミデートを含有し、N末端におけるAhx(6-アミノヘキサン酸)残基の付加を伴った。
AONの合成
ペプチド-AONコンジュゲートの合成
環状ペプチドのコンジュゲーションが、AONのエクソンスキッピング能に影響を及ぼすのかどうかを決定するために、ID25-h45コンジュゲートを、活性について評価し、トランスフェクション試薬を伴わないヒト対照筋管(2μM)と共に、96時間にわたりインキュベートした(図4)。結果は、二連の2つの独立の実験の平均を示し、in vitroにおけるコンジュゲーションの、否定的な影響を指し示さない。
4週齢のmdxマウス(群1つ当たりのn=4~5)に、毎週4回ずつ、50mg/kgのm23、モル当量のID24-m23、ID25-m23、又は生理食塩水を、8週間にわたり皮下投与した。最終回の注射の一週間後に、目的の組織を単離した。RNAを単離し、単回のRT-PCRにより、エクソンスキッピングレベルを評価し(図5A)、ラボオンチップ解析により、半定量的に決定した。ジストロフィンタンパク質レベルは、ウェスタンブロットにより決定した(図5B)。初回の注射の後、血液試料を、いくつかの時点及び屠殺時に採取して、血漿におけるAONレベルを決定した(図5C)。ハイブリダイゼーション-ライゲーションアッセイを使用して、組織におけるAONレベルを決定した(図5D)。バーは、平均値±SDを表す。有意であるP<0.05のための、事後検定(ボンフェローニ)を伴う一元ANOVAである。G=腓腹筋、Q=大腿四頭筋、Ti=前腓骨筋、Tr=三頭筋、H=心臓、D=横隔膜、L=肝臓、K=腎臓である。
発明の態様及び実施形態
第一の態様
第一の形態は、(i)配列番号24、25、1~23、26~63からなる群から選択されるターゲティング配列を含むか、又はこれらからなるペプチド又はペプチド模倣体のコンジュゲートであって、前記ペプチド又はペプチド模倣体が、(ii)生物学的活性部分及び診断用部分から選択される部分へと連結されたコンジュゲート(実施形態1)を提供する。
実施形態1における好ましいコンジュゲートにおいて、前記生物学的活性部分が、2’-O-アルキル、特に、2’-O-メトキシエチル及び2’-O-メチル、架橋/二環式核酸のヌクレオチド(LNA、ENA、cEt、CBBN、CRN、アルファ-L-LNA、cMOE、2’-アミノ-LNA、2’-(アシルアミノ)LNA、2’-チオ-LNA、BNA NC [N-Me]、BNA NC [NH])、トリシクロDNA(tcDNA)、ペプチド核酸(PNA、PPNA)、ホスホロチオエート修飾ヌクレオチド、キラルに規定されたホスホロチオエート修飾ヌクレオチド、ホスホリルグアニジン修飾オリゴヌクレオチド(PGO)、モルホリノベースのヌクレオチド(PMO、PMO+、PMO-X、PPMO)、及びこれらの組合せを含む化合物など、DNA、RNA、及びこれらの類似体からなる群から選択される(実施形態2)。
本態様の実施形態1又は2における好ましいコンジュゲートは、実施形態1のペプチドと、前記生物学的活性部分又は前記診断用部分との融合タンパク質であり、前記生物学的活性部分が、治療的に活性であるタンパク質である、及び/又は前記診断用部分が、診断用タンパク質である(実施形態3)。
本態様の実施形態1~3のいずれかにおける好ましいコンジュゲートは、核局在化シグナル又は細胞透過性ペプチドをさらに含む(実施形態4)。
本態様の実施形態1~4のいずれかにおける好ましいコンジュゲートは、前記ペプチド又はペプチド模倣体が、環状である(実施形態5)。より好ましくは、前記ペプチド又は前記ペプチド模倣体が、フランキング部分を含み、前記フランキング部分が、前記ターゲティング配列を挟むアミノ酸残基又は他の部分を含むか、又はこれらからなり、前記フランキング部分が、互いとの結合を形成する(実施形態6)。さらに好ましくは、前記フランキング部分が、ジスルフィド架橋を形成し、好ましくは、前記フランキング部分が、システイン残基を含むか、又はこれらからなる(実施形態7)。
本態様の実施形態6又は7における好ましいコンジュゲートにおいて、前記フランキング部分が、前記ターゲティング配列から、4、3、2、1、又は0残基隔てられており、好ましくは、前記フランキング部分が、前記ターゲティング配列と隣接している(実施形態8)。
本態様の実施形態1~8のいずれかにおける好ましいコンジュゲートは、医薬としての使用のためである(実施形態9)。より好ましくは、前記生物学的活性部分又は前記診断用部分を、筋細胞へとターゲティングするためである(実施形態10)。
本態様の実施形態9又は10における好ましいコンジュゲートは、心障害を含む筋細胞関連障害の処置のため(実施形態11)、又は、自己免疫疾患、代謝性障害、肥満、又はII型糖尿病の処置のための医薬である(実施形態12)。
本態様の実施形態9~11のいずれかにおける好ましいコンジュゲートは、ミオパチー、筋ジストロフィー、又は筋肉消耗疾患の処置のためである(実施形態13)。
本態様の実施形態1~8のいずれかにおける好ましいコンジュゲートにおいて、前記ターゲティング配列が、配列番号1~25からなる群から選択され(実施形態14)、より好ましくは、配列番号14~25からなるから選択され(実施形態15)、さらに好ましくは配列番号24~25からなる群から選択される(実施形態16)。
本態様の実施形態9~13のいずれかにおける好ましいコンジュゲートにおいて、前記ターゲティング配列が、配列番号1~25からなる群から選択され(実施形態17)、より好ましくは、配列番号14~25からなるから選択され(実施形態18)、さらに好ましくは配列番号24~25からなる群から選択される(実施形態19)。
第二の態様
本発明の第二の態様において、第一の態様の実施形態1~8のいずれかで定義されたペプチド又はペプチド模倣体と、前記ペプチド又はペプチド模倣体を、生物学的活性部分又は診断用部分へと連結するためのリンカー部分であって、ペプチドではないリンカー部分とを含む分子を提供する(第二の態様の実施形態1)。
第二の態様の実施形態1の好ましい分子において、前記ターゲティング配列が、配列番号1~25からなる群から選択され(第二の態様の実施形態2)、より好ましくは、配列番号14~25からなるから選択され(第二の態様の実施形態3)、さらに好ましくは配列番号24~25からなる群から選択される(第二の態様の実施形態4)。
Claims (13)
- (i)配列番号24及び25からなる群から選択されるターゲティング配列を含むペプチド又はペプチド模倣体のコンジュゲートであって、前記ペプチド又はペプチド模倣体が、環状であり、かつ、最大で30アミノ酸の長さを有し、前記ペプチド又はペプチド模倣体が、(ii)生物学的活性部分、検出用部分及び診断用マーカーから選択される部分へと連結されたコンジュゲート。
- 前記生物学的活性部分が、DNA、RNA、及びこれらの類似体からなる群から選択される、請求項1に記載のコンジュゲート。
- 前記生物学的活性部分が、2’-O-アルキル、架橋/二環式核酸のヌクレオチド、トリシクロDNA、ペプチド核酸、ホスホロチオエート修飾ヌクレオチド、キラルに規定されたホスホロチオエート修飾ヌクレオチド、ホスホリルグアニジン修飾オリゴヌクレオチド、モルホリノベースのヌクレオチド、及びこれらの組合せからなる群から選択される、請求項2に記載のコンジュゲート。
- 請求項1に記載のペプチドと、前記生物学的活性部分、前記検出用部分又は前記診断用マーカーとの融合タンパク質であり、前記生物学的活性部分が、治療的に活性であるタンパク質である、及び/又は前記診断用マーカーが、診断用タンパク質である、請求項1~3のいずれか一項に記載のコンジュゲート。
- 核局在化シグナル又は細胞透過性ペプチドをさらに含む、請求項1~4のいずれか一項に記載のコンジュゲート。
- 前記ペプチド又は前記ペプチド模倣体が、フランキング部分を含み、前記フランキング部分が、前記ターゲティング配列を挟むアミノ酸残基又は他の部分を含むか、又はこれらからなり、前記フランキング部分が、互いとの結合を形成する、請求項1~5のいずれか一項に記載のコンジュゲート。
- 前記フランキング部分が、ジスルフィド架橋を形成する、請求項6に記載のコンジュゲート。
- 前記フランキング部分が、前記ターゲティング配列から、4、3、2、1、又は0残基隔てられている、請求項6又は7に記載のコンジュゲート。
- 請求項1~8のいずれか一項に記載のコンジュゲートと、薬学的に許容される担体とを含む、前記生物学的活性部分、前記検出用部分又は前記診断用マーカーを、筋細胞へとターゲティングするための医薬組成物。
- 請求項1~8のいずれか一項に記載のコンジュゲートと、薬学的に許容される担体とを含む、心障害を含む筋細胞関連障害の処置のための医薬組成物。
- ミオパチー、筋ジストロフィー、又は筋肉消耗疾患の処置のための、請求項9又は10に記載の医薬組成物。
- 請求項1~8のいずれか一項に記載のコンジュゲートと、薬学的に許容される担体とを含む、自己免疫疾患、代謝性障害、肥満、又はII型糖尿病の処置のための医薬組成物。
- 請求項1~8のいずれか一項に記載のペプチド又はペプチド模倣体と、
前記ペプチド又はペプチド模倣体を、生物学的活性部分、検出用部分又は診断用マーカーへと連結するためのリンカー部分であって、ペプチドではないリンカー部分と
を含む分子。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16199033.8 | 2016-11-16 | ||
EP16199033 | 2016-11-16 | ||
PCT/EP2017/079349 WO2018091544A1 (en) | 2016-11-16 | 2017-11-15 | Substances for targeting various selected organs or tissues |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2020510612A JP2020510612A (ja) | 2020-04-09 |
JP7060216B2 true JP7060216B2 (ja) | 2022-04-26 |
Family
ID=57326281
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019526295A Active JP7060216B2 (ja) | 2016-11-16 | 2017-11-15 | 多様な選択された臓器又は組織をターゲティングするための物質 |
Country Status (12)
Country | Link |
---|---|
US (1) | US11459358B2 (ja) |
EP (1) | EP3541829A1 (ja) |
JP (1) | JP7060216B2 (ja) |
KR (1) | KR102646799B1 (ja) |
CN (1) | CN110267970A (ja) |
AU (1) | AU2017361784B2 (ja) |
BR (1) | BR112019009953A2 (ja) |
CA (1) | CA3043864A1 (ja) |
IL (1) | IL266690B1 (ja) |
MX (1) | MX2019005671A (ja) |
RU (1) | RU2759022C2 (ja) |
WO (1) | WO2018091544A1 (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI541024B (zh) | 2010-09-01 | 2016-07-11 | 日本新藥股份有限公司 | 反義核酸 |
KR20210081324A (ko) | 2018-08-02 | 2021-07-01 | 다인 세라퓨틱스, 인크. | 근육 표적화 복합체 및 안면견갑상완 근육 이영양증을 치료하기 위한 그의 용도 |
US20210308273A1 (en) | 2018-08-02 | 2021-10-07 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
EP4330395A1 (en) | 2021-04-30 | 2024-03-06 | Sarepta Therapeutics, Inc. | Treatment methods for muscular dystrophy |
US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
WO2023178230A1 (en) | 2022-03-17 | 2023-09-21 | Sarepta Therapeutics, Inc. | Phosphorodiamidate morpholino oligomer conjugates |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040123343A1 (en) | 2000-04-19 | 2004-06-24 | La Rosa Thomas J. | Rice nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement |
JP2010533171A (ja) | 2007-07-12 | 2010-10-21 | プロセンサ テクノロジーズ ビー.ブイ. | 化合物を種々の選択臓器又は組織に標的化するための分子 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7504490B1 (en) * | 1998-10-16 | 2009-03-17 | Oscient Pharmaceuticals Corporation | Nucleic acid and amino acid sequences relating to Apergillus fumigatus for diagnostics and therapeutics |
EP1250355A1 (en) | 2000-01-21 | 2002-10-23 | The Burnham Institute | Chimeric prostate-homing peptides with pro-apoptotic activity |
KR20090098710A (ko) | 2008-03-14 | 2009-09-17 | 주식회사 씨티아이바이오 | 세포투과성과 핵산 결합력이 좋은 펩타이드 핵산 유도체 |
US20130059902A1 (en) | 2010-02-08 | 2013-03-07 | Isis Pharmaceuticals, Inc. | Methods and compositions useful in treatment of diseases or conditions related to repeat expansion |
BR112014018427B1 (pt) | 2012-01-27 | 2021-11-03 | Biomarin Technologies B.V. | Oligonucleotídeos moduladores de rna com características melhoradas para o tratamento da distrofia muscular de duchenne e becker |
WO2013131019A1 (en) | 2012-03-02 | 2013-09-06 | Ludwig Institute For Cancer Research Ltd. | Iaspp phosphorylation and metastatic potential |
JP6460983B2 (ja) | 2012-07-03 | 2019-01-30 | バイオマリン テクノロジーズ ベー.フェー. | 筋ジストロフィー患者の治療のためのオリゴヌクレオチド |
WO2014112463A1 (ja) | 2013-01-15 | 2014-07-24 | 国立大学法人大阪大学 | スルホンアミド構造を有するヌクレオシドおよびヌクレオチド |
US9315535B2 (en) | 2013-02-18 | 2016-04-19 | Shionogi & Co., Ltd. | Nucleoside and nucleotide having nitrogen-containing heterocycle structure |
MX364814B (es) | 2013-03-15 | 2019-05-08 | Miragen Therapeutics Inc | Nucleosidos biciclicos unidos en puente. |
WO2015142910A1 (en) | 2014-03-17 | 2015-09-24 | Isis Pharmaceuticals, Inc. | Bicyclic carbocyclic nucleosides and oligomeric compounds prepared therefrom |
DE102014007158A1 (de) | 2014-05-16 | 2015-11-19 | Ugichem Gmbh | Neue Peptid-Nukleinsäuren-Monomere und -Oligomere |
WO2016017422A1 (ja) | 2014-07-31 | 2016-02-04 | 国立大学法人大阪大学 | 架橋型ヌクレオシドおよびヌクレオチド |
-
2017
- 2017-11-15 WO PCT/EP2017/079349 patent/WO2018091544A1/en unknown
- 2017-11-15 CA CA3043864A patent/CA3043864A1/en active Pending
- 2017-11-15 CN CN201780084026.0A patent/CN110267970A/zh active Pending
- 2017-11-15 BR BR112019009953A patent/BR112019009953A2/pt unknown
- 2017-11-15 IL IL266690A patent/IL266690B1/en unknown
- 2017-11-15 KR KR1020197016928A patent/KR102646799B1/ko active IP Right Grant
- 2017-11-15 EP EP17804132.3A patent/EP3541829A1/en active Pending
- 2017-11-15 JP JP2019526295A patent/JP7060216B2/ja active Active
- 2017-11-15 AU AU2017361784A patent/AU2017361784B2/en active Active
- 2017-11-15 RU RU2019118041A patent/RU2759022C2/ru active
- 2017-11-15 MX MX2019005671A patent/MX2019005671A/es unknown
- 2017-11-15 US US16/461,313 patent/US11459358B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040123343A1 (en) | 2000-04-19 | 2004-06-24 | La Rosa Thomas J. | Rice nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement |
JP2010533171A (ja) | 2007-07-12 | 2010-10-21 | プロセンサ テクノロジーズ ビー.ブイ. | 化合物を種々の選択臓器又は組織に標的化するための分子 |
Also Published As
Publication number | Publication date |
---|---|
RU2759022C2 (ru) | 2021-11-08 |
KR102646799B1 (ko) | 2024-03-15 |
CN110267970A (zh) | 2019-09-20 |
IL266690A (en) | 2019-07-31 |
BR112019009953A2 (pt) | 2019-10-08 |
JP2020510612A (ja) | 2020-04-09 |
US11459358B2 (en) | 2022-10-04 |
AU2017361784A1 (en) | 2019-07-04 |
CA3043864A1 (en) | 2018-05-24 |
AU2017361784A9 (en) | 2019-09-05 |
WO2018091544A1 (en) | 2018-05-24 |
AU2017361784B2 (en) | 2021-07-15 |
US20210347825A1 (en) | 2021-11-11 |
IL266690B1 (en) | 2024-02-01 |
WO2018091544A8 (en) | 2019-03-28 |
RU2019118041A (ru) | 2020-12-17 |
KR20190104021A (ko) | 2019-09-05 |
EP3541829A1 (en) | 2019-09-25 |
RU2019118041A3 (ja) | 2021-03-02 |
MX2019005671A (es) | 2020-07-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7060216B2 (ja) | 多様な選択された臓器又は組織をターゲティングするための物質 | |
JP5706157B2 (ja) | 化合物を種々の選択臓器又は組織に標的化するための分子 | |
ES2674929T3 (es) | Análogos oligonucleotídicos dirigidos a LMNA humana | |
ES2694726T3 (es) | Conjugados peptídicos específicos de tejido y métodos | |
CA2846218C (en) | Cell-penetrating peptides having a central hydrophobic domain | |
JP2010533170A (ja) | 化合物を種々の選択された臓器、組織又は腫瘍細胞に標的化するための分子 | |
JP2014508521A (ja) | 細胞内へのカーゴ送達のためのシステム | |
WO2023034818A1 (en) | Compositions and methods for skipping exon 45 in duchenne muscular dystrophy | |
Bhosle | Arginine-rich tat-and (RXR)-motif peptidomimetics for DNA/RNA binding, antimicrobial action and cell penetration | |
WO2023026994A1 (ja) | ヒトトランスフェリンレセプター結合ペプチド-薬物コンジュゲート | |
ES2577712T3 (es) | Moléculas para direccionar compuestos a varios órganos o tejidos seleccionados | |
Zahid et al. | CTP_Biomolecules_2018. pdf | |
AU2015200600B2 (en) | Tissue specific peptide conjugates and methods | |
Thakur et al. | The role of radiolabeled peptide nucleic acid chimeras and peptides in imaging oncogene expression |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190717 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20190912 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20201104 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20210330 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20210330 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210928 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20211224 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20220204 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220222 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220315 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220405 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7060216 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |